Compare Cytokinetics Inc (CYTK) vs ProShares Ultra Gold ETF (UGL) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Cytokinetics Inc vs ProShares Ultra Gold ETF — how do they compare? Cytokinetics Inc trades at $61.95 (market cap $8.62B), while ProShares Ultra Gold ETF trades at $46.05 (market cap $716.59M). The key difference: Cytokinetics Inc is far larger — about 12× ProShares Ultra Gold ETF's market cap, and Cytokinetics Inc is trading nearer its 52-week high, ProShares Ultra Gold ETF nearer its low. Which is the better fit depends on your goals — on Pluang, investors hold Cytokinetics Inc for 19 Days and ProShares Ultra Gold ETF for 23 Days on average.
| CYTK | UGL | |
|---|---|---|
Market Cap | $8.62B | $716.59M |
Volume | 2,594,626 | 2,592,878 |
Sector | Health | Leveraged / Inverse |
52-Week High | $87.26 | $85.62 |
52-Week Low | $54.76 | $42.79 |
Typical Hold Time | 19 Days | 23 Days |
Enterprise Value | $8.72B | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Cytokinetics (CYTK) trades at $61.12, down 0.37% on the day, with a bearish technical signal from moving averages despite some oversold RSI readings. The company reported a net loss of $784.96 million on $88.04 million revenue in 2025, with a negative net income margin of -1,321.12% in 2026. Recent news highlights clinical progress for aficamten in hypertrophic cardiomyopathy and executive stock sales.
Wall Street maintains strong bullish sentiment with a 97.14% buy rating and $112.60 consensus price target, but high cash burn, persistent losses, and insider selling pose significant risks. The stock's outlook hinges on successful commercialization of its heart failure pipeline amid substantial financial and competitive pressures.
UGL shares are trading at $44.43, down 3.29% with a bearish technical outlook as moving averages and oscillators signal selling pressure. The stock faces resistance at $45-$46 with support at $43-$44. Recent market sentiment reflects concerns about gold's performance amid rising Treasury yields and Federal Reserve policy uncertainty, creating headwinds for gold-related equities.
The stock's outlook remains challenged by macroeconomic pressures on gold prices, though potential Fed policy shifts could provide catalysts. Key risks include persistent high yields and dollar strength, while opportunities exist if inflation concerns reignite safe-haven demand. Investors should monitor Fed guidance and gold price trends for directional cues.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
About Cytokinetics Inc
Cytokinetics is a biopharmaceutical company focused on muscle biology. It develops muscle activators and inhibitors as potential treatments for debilitating diseases where muscle performance is compromised or declining.
Read more on CYTK →About ProShares Ultra Gold ETF
UGL is a leveraged ETF that seeks daily investment results, before fees and expenses, that correspond to two times (2x) the daily performance of the Bloomberg Gold Subindex. It is a tactical tool designed for sophisticated investors to magnify short-term bullish views on gold prices through the use of futures and swap contracts, rather than holding physical bullion.
Read more on UGL →
